Business
Med Biogene Inc. receives renewed ethics board approval from Vancouver Coastal Health Authority; expects to release pre-clinical results of Diagnostic Lymphoma Bioarray shortly
Med Biogene Inc. receives renewed ethics board approval from Vancouver Coastal Health Authority; expects to release pre-clinical results of Diagnostic Lymphoma Bioarray shortly.
About this update from Many Bright Ideas Technologies Inc
[{"type":"text","content":"\n\n\n\n\nVANCOUVER, Aug. 1 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) is pleased\nto announce that it has received renewed ethics board approval from the\nVancouver Coastal Health Authority. MBI received initial ethics board approval\nin June 2005. As contemplated in the study protocol, Lion's Gate Hospital will\nprovide to MBI blood and tumour tissue samples of confirmed lymphoma patients,\nand blood samples of confirmed leukemia patients.\nMBI will use these samples to continue its pre-clinical studies of\nvalidating its Hematological Cancer Profiling System relating to its\nDiagnostic Lymphoma Bioarray and Diagnostic Leukemia Bioarray.\n\"Med BioGene is very pleased to have received renewed ethics board\napproval from the Vancouver Coastal Health Authority. We are aggressively\nvalidating our biomarkers for our Diagnostic Lymphoma Bioarray and Diagnostic\nLeukemia Bioarray and we expect to release our pre-clinical results relating\nto our Diagnostic Lymphoma Bioarray shortly\" stated Erinn Broshko, Chief\nExecutive Officer of MBI.\n\nAbout Med BioGene\n\nMBI is a biotechnology company with advanced research expertise in gene\nexpression technology. MBI's mission is to become the market leader in the\nsupply of content for molecular-based diagnostic micro arrays. MBI intends to\nfulfill this mission by developing and marketing genetic content for\nmolecular-based human diagnostic tests. Molecular diagnostics, based on\ngenetic expression, is a developing technology field that has the potential to\nreplace certain of today's standard diagnostic tests. MBI intends to utilize\nits expertise in gene expression, bioinformatics and micro arrays to develop\nthe diagnostic tests' genetic content. From the tens of thousands of genes in\nthe human genome, MBI is identifying those genes, known as \"biomarkers,\" which\nmark the presence of various disease conditions.\nMBI's initial focus will be developing diagnostic tests for certain types\nof cancer, specifically lymphoma and leukemia. In the future, MBI intends to\ndevelop diagnostic tests to identify the earliest stages of heart disease or\nthe presence of an infectious disease. These diagnostic test kits will be\ndesigned to provide additional information to physicians to allow them to\ncreate more suitable and more effective treatments for an improved patient\nprognosis.\n\nThe T...